Imatinib Mesylate
Brand name: Imatinib Mesylate
Rank #181 of 500 drugs by total cost
$85.0M
Total Cost
40,908
Total Claims
$85.0M
Total Cost
1,931
Prescribers
$2,079
Cost per Claim
215
Beneficiaries
42,531
30-Day Fills
$44K
Avg Cost/Provider
21
Avg Claims/Provider
About Imatinib Mesylate
Imatinib Mesylate (sold as Imatinib Mesylate) was prescribed 40,908 times by 1,931 Medicare Part D providers in 2023, costing the program $85.0M. At $2,079 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 178 | Insulin Aspart Prot/Insuln Asp (Novolog Mix 70-30 Flexpen) | $88.8M | 79,814 |
| 179 | Teduglutide (Gattex) | $88.4M | 1,758 |
| 180 | Galcanezumab-Gnlm (Emgality Pen) | $87.0M | 101,221 |
| 181 | Imatinib Mesylate (Imatinib Mesylate) | $85.0M | 40,908 |
| 182 | Clopidogrel Bisulfate (Clopidogrel) | $84.7M | 5,428,304 |
| 183 | Famotidine (Famotidine) | $84.3M | 5,257,365 |
| 184 | Mifepristone (Korlym) | $83.3M | 2,397 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology